Meeting objectives and introduction
David Maloney & Frederick Locke

Welcome to the solid tumors day
Kedar Kirtane & Allison Betof

 Session 1: CARs targeting cell surface proteins (part I)
Chairs: Saul Priceman & Jennifer Specht

• Targeting DTP cells to advance CAR T-cell therapy for solid tumors – NSCLC as a model: TBC
• Talk title TBC: Benjamin Schlecter
• Talk title TBC: David Steffin
•  Intracerebroventricular dual-targeting CAR T cells for glioblastoma: are we on the right path?: Stephen Bagley
• Talk title TBC: Jennifer Specht

Panel discussion

Keynote talk 1
Talk title TBC: John Haanen

Break

Session 2: CARs targeting cell surface proteins (part II)
Chairs: Eric Smith & TBC                                                                   

• Talk title TBC: TBC
• B7H3 CAR-T cell therapy in recurrent platinum resistant epithelial ovarian cancer: Oliver Dorigo
• Talk title TBC: Roisin O’Cearbhaill
• Talk title TBC: Jeffrey Ward
• Training T cells for the harsh new world (of solid tumors): Saul Priceman

Panel discussion

Session 3: T-cell engagers and TCRs for solid tumors
Chairs: Allison Betof & TBC                                                                                                         

• Talk title TBC: TBC
• Talk title TBC: TBC
• Talk title TBC: TBC
• Talk title TBC: TBC
• Talk title TBC: TBC
• Talk title TBC: TBC

Panel discussion

Lunch

Session 4: TILs for solid tumors
Chairs: Allison Betof & Benjamin Creelan  

• OBX-115 in advanced melanoma: Rodabe Amaria
• Talk title: TBC
• Enrichment strategies for TIL in NSCLC: Benjamin Creelan
• Talk title: Daniel Olson

Panel discussion           

Session 5: Novel technologies in solid tumors
Chairs: TBC & TBC

• Engineered HSCs for solid tumors: TBC
• Cytokine receptor engineering to supercharge CAR T-cells: Sebastian Kobold
• Armored CARs in solid tumors: Renier Brentjens
• Utilizing ex vivo CAR T-cell therapy for gastric/GEJ cancers: Changsong Qi

Panel discussion

Break

Session 6: CARs for autoimmune rheumatic disorders
Chairs: David Porter & Jeremias Motte

• Talk title TBC: Melanie Hagen
• Talk title TBC: Pere Barba
• Talk title TBC: TBC
• Talk title TBC: TBC

Panel discussion

Day 1 conclusions
Kedar Kirtane & Allison Betof

 

Welcome reception

Welcome to Day 2
Claire Roddie & Caron Jacobsen

Keynote talk 2
Talk title TBC: Patrick Hwu  

Session 7: CARs for neurological autoimmune diseases
Chairs: Claire Roddie & TBC

• Talk title TBC: TBC
• Talk title TBC: Jeremias Motte
• Talk title TBC: Matthew Lunning
• Talk title TBC: Tuan Vu

Panel discussion

Break

Session 8: T-cell engagers and CARs in CLL
Chairs: Alexey Danilov & TBC

• Talk title TBC: Tanya Siddiqi
• Talk title TBC: Mazyar Shadman
• Talk title TBC: Michael Bishop

Panel discussion

Session 9: T-cell engagers and CARs in ALL
Chairs: Noelle Frey & Pere Barba

• New generation of CD19-bispecifics in ALL: Ibrahim Aldoss
• Dual-antigen targeting trial in B-ALL: Nirav Shah
• Real-world evidence with obe-cel: Bijal Shah

Panel discussion

Lunch

Session 10: T-cell engagers and CARs in myeloid malignancies
Chairs: David Sallman & TBC

• Talk title TBC: Stephen Strickland
• Talk title TBC: Maher Abdul-Hay
• Talk title TBC: Rizwan Romee
• Advances with CAR T-cell therapy in pediatric AML: Swati Naik
• Talk title TBC: Tim Sauer

Panel discussion

Session 11: T-cell engagers in lymphoma
Chairs: Jason Westin & TBC

• The emerging role of mosunetuzumab as frontline therapy of follicular lymphoma: Lorenzo Falchi
• Talk title TBC: Alexey Danilov
• Talk title TBC: Jason Westin

Panel discussion

Break

Session 12: CARs in lymphoma
Chairs: Jeremy Abramson & Gloria Inés Iacoboni García-Calvo

• Talk title TBC: Paolo Strati
• CD5 CAR for T cell lymphoma: Marco Ruella
• JAK inhibition and CAR T-cell therapy: Michael Jain
• Talk title TBC: TBC

Panel discussion

Session 13: CD19/20 CARs in lymphoma
Chairs: David Miklos & Marie José Kersten

• CD19/CD20 dual targeting CAR T in 2L+ DLBCL: Key data from Prizlo-cel (formerly JNJ-4496): Krish Patel
• Talk title TBC: Saurabh Dahiya
• Talk title TBC: Nirav Shah
• Talk title TBC: Akil Merchant
• Talk title TBC: Marie José Kersten

Panel discussion

Day 2 conclusions
Caron Jacobsen

 

Faculty dinner

Welcome to Day 3
Frederick Locke

Keynote talk 3
The lymphoma microenvironment and resistance to CAR T-cell therapy: Michael Green

Session 14: Navigating the broader challenges in CAR T-cell therapy
Chairs: Sarah Nikiforow & Frederick Locke

• Talk title TBC (toxicities): Kai Rajeski
• Talk title TBC (regulatory landscape): TBC
• Talk title TBC (relative cost vs BsABs): TBC
• Talk title TBC (access challenges): Tara Graff

Panel discussion

Session 15: in vivo CARs in lymphoma and myeloma
Chairs: Saar Gill & TBC

• Talk title TBC: Michael Bishop
• Talk title TBC: TBC
• Talk title TBC: TBC
• Talk title TBC: Kah Whye Peng

Panel discussion

Break

Session 16: CARs for multiple myeloma
Chairs: Francesco Maura & Matthew Frigault

• Evergreen CAR factory to enhance persistence: Eric Smith
• Talk title TBC: TBC
• Talk title TBC: Rakesh Popat
• Talk title TBC: Ciara Freeman
• Talk title TBC: Juan Du
• Talk title TBC: Sham Mailankody

Panel discussion

Session 17: T-cell engagers for multiple myeloma
Chairs: Doris Hansen & Yi Lin

• Talk title TBC: TBC
• Talk title TBC: TBC
• Talk title TBC: Paula Rodríguez Otero
• Talk title TBC: Adam Cohen

Panel discussion

Meeting conclusions
Frederick Locke & David Maloney

Lunch and adjourn